Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash from Financing Activities for 9 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 107.69% to -$2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $218.0 million through Dec 2025, up 13.97% year-over-year, with the annual reading at $218.0 million for FY2025, 13.97% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$2.9 million at Rhythm Pharmaceuticals, down from $189.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $189.3 million in Q3 2025, with the low at -$2.9 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $43.2 million, with a median of $3.4 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities soared 38293.22% in 2022, then tumbled 133.33% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $100000.0 in 2021, then surged by 17265.0% to $17.4 million in 2022, then plummeted by 86.05% to $2.4 million in 2023, then skyrocketed by 1481.84% to $38.3 million in 2024, then tumbled by 107.69% to -$2.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$2.9 million, $189.3 million, and -$889000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.